Description: Baylor College of Medicine is one of about 50 sites in the US participating in this trial. The purpose of the study is to see if it is possible to predict if a person will develop mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) based on his/her genes and to test a medicine called pioglitazone (AD-4833) to see if it will delay the first symptoms of MCI due to AD in people whose memory and thinking are currently normal yet thought to be at high risk for developing this condition. Pioglitazone is thought to work by decreasing inflammation in the brain, unlike other investigational drugs which interrupt the formation of amyloid plaques. It is anticipated that it will take five years to complete the trial. Individuals with high risk will be assigned to either AD-4833 or placebo while those with low risk will be assigned to placebo.
Eligibility: A person may be eligible to participate if he or she is between 65 and 83 years of age, is not demented or taking medication for the treatment of Alzheimer's disease, and has a partner or caregiver who will accompany them to study visits every six months.
For more information contact Sayo Awosika-Olumo at (713) 798-7433 or email email@example.com.